Silexion Therapeutics CORP S-1 registration statements

Silexion Therapeutics Corp. has filed an S-1 registration statement with the SEC to offer ordinary shares and warrants, detailing its clinical-stage oncology drug development and ongoing financing activities.

Silexion Therapeutics Corp files an S-1 for a best-efforts public offering of up to 832,177 ordinary shares and warrants, while addressing significant operating losses and Nasdaq listing compliance challenges.

Silexion Therapeutics Corp filed an S-1 registration statement for the resale of ordinary shares, highlighting significant operating losses, a going concern doubt, and recent capital raises to fund its clinical-stage oncology programs.

Silexion Therapeutics is amending its S-1 registration statement to allow selling securityholders to resell up to 2,377,030 ordinary shares following a 1-for-9 reverse stock split.

Silexion Therapeutics is registering for resale up to 2.38 million ordinary shares by selling securityholders, primarily from warrant exercises.

Silexion Therapeutics launches a best-efforts offering to raise up to $5 million for advancing its RNAi-based cancer therapies, including SIL-204B for pancreatic cancer.

Silexion Therapeutics is launching a best-efforts offering to raise up to $5 million for advancing its RNAi-based cancer therapies.

Silexion Therapeutics Corp files for an IPO to offer ordinary shares, pre-funded warrants, and related warrants, aiming to advance its oncology-focused pipeline.

Silexion Therapeutics is registering the resale of ordinary shares and warrants by selling securityholders, along with the issuance of ordinary shares upon warrant exercise.

Silexion Therapeutics aims to raise up to $15 million through an equity line of credit with White Lion Capital, as detailed in a recent S-1 filing.